| Dr Girish Juneja, MD | |
|
20095 Gilbert Rd, Big Rapids, MI 49307-2365 | |
| (231) 592-1360 | |
| Not Available |
| Full Name | Dr Girish Juneja |
|---|---|
| Gender | Male |
| Speciality | Pain Management |
| Experience | 35 Years |
| Location | 20095 Gilbert Rd, Big Rapids, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114904349 | NPI | - | NPPES |
| 3461754 | Medicaid | MI | |
| 4603498 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2081P2900X | Physical Medicine & Rehabilitation - Pain Medicine | 4301069459 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Spectrum Health | Grand rapids, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| West Michigan Pain Center Pc | 1355717331 | 4 |
| Michigan Primary Care Partners P C | 8527044551 | 16 |
News Archive
In an attempt to overcome these issues, a team of researchers from various departments at the University of California San Diego recently proposed using biomimetic virus-like particles (VLPs) as positive controls for assays used in SARS-CoV-2 detection. Their study is published on the preprint server bioRxiv.
EUROSARC, European Clinical trials in Rare Sarcomas within an integrated translational trial network, has launched a phase II trial of Linsitinib for patients with relapsed and/or refractory Ewing Sarcoma. The trial, EORTC 1225 / OCTO 038, aims to establish pharmacodynamic responses in Ewing sarcoma tumors to Linsitinib using functional imaging and biopsies, and toxicity and clinical outcomes.
In collaboration with the American Cancer Society and the Centers for Disease Control and Prevention, the George Washington University Cancer Institute is launching the Cancer Survivorship E-Learning Series for Primary Care Providers on April 15, 2013.
Members of the public in sub-Saharan Africa who are carriers of the hereditary disease sickle cell disease must be educated aggressively through public health campaigns to raise awareness of the risks of parenting offspring with the disease if their partner is also a carrier, according to research published in the International Journal of Medical Engineering and Informatics.
› Verified 8 days ago
| Entity Name | Michigan Primary Care Partners P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366497380 PECOS PAC ID: 8527044551 Enrollment ID: O20040629000594 |
News Archive
In an attempt to overcome these issues, a team of researchers from various departments at the University of California San Diego recently proposed using biomimetic virus-like particles (VLPs) as positive controls for assays used in SARS-CoV-2 detection. Their study is published on the preprint server bioRxiv.
EUROSARC, European Clinical trials in Rare Sarcomas within an integrated translational trial network, has launched a phase II trial of Linsitinib for patients with relapsed and/or refractory Ewing Sarcoma. The trial, EORTC 1225 / OCTO 038, aims to establish pharmacodynamic responses in Ewing sarcoma tumors to Linsitinib using functional imaging and biopsies, and toxicity and clinical outcomes.
In collaboration with the American Cancer Society and the Centers for Disease Control and Prevention, the George Washington University Cancer Institute is launching the Cancer Survivorship E-Learning Series for Primary Care Providers on April 15, 2013.
Members of the public in sub-Saharan Africa who are carriers of the hereditary disease sickle cell disease must be educated aggressively through public health campaigns to raise awareness of the risks of parenting offspring with the disease if their partner is also a carrier, according to research published in the International Journal of Medical Engineering and Informatics.
› Verified 8 days ago
| Entity Name | West Michigan Pain Center Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447973060 PECOS PAC ID: 1355717331 Enrollment ID: O20221017000292 |
News Archive
In an attempt to overcome these issues, a team of researchers from various departments at the University of California San Diego recently proposed using biomimetic virus-like particles (VLPs) as positive controls for assays used in SARS-CoV-2 detection. Their study is published on the preprint server bioRxiv.
EUROSARC, European Clinical trials in Rare Sarcomas within an integrated translational trial network, has launched a phase II trial of Linsitinib for patients with relapsed and/or refractory Ewing Sarcoma. The trial, EORTC 1225 / OCTO 038, aims to establish pharmacodynamic responses in Ewing sarcoma tumors to Linsitinib using functional imaging and biopsies, and toxicity and clinical outcomes.
In collaboration with the American Cancer Society and the Centers for Disease Control and Prevention, the George Washington University Cancer Institute is launching the Cancer Survivorship E-Learning Series for Primary Care Providers on April 15, 2013.
Members of the public in sub-Saharan Africa who are carriers of the hereditary disease sickle cell disease must be educated aggressively through public health campaigns to raise awareness of the risks of parenting offspring with the disease if their partner is also a carrier, according to research published in the International Journal of Medical Engineering and Informatics.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Girish Juneja, MD 20095 Gilbert Rd, Big Rapids, MI 49307-2365 Ph: (231) 592-1360 | Dr Girish Juneja, MD 20095 Gilbert Rd, Big Rapids, MI 49307-2365 Ph: (231) 592-1360 |
News Archive
In an attempt to overcome these issues, a team of researchers from various departments at the University of California San Diego recently proposed using biomimetic virus-like particles (VLPs) as positive controls for assays used in SARS-CoV-2 detection. Their study is published on the preprint server bioRxiv.
EUROSARC, European Clinical trials in Rare Sarcomas within an integrated translational trial network, has launched a phase II trial of Linsitinib for patients with relapsed and/or refractory Ewing Sarcoma. The trial, EORTC 1225 / OCTO 038, aims to establish pharmacodynamic responses in Ewing sarcoma tumors to Linsitinib using functional imaging and biopsies, and toxicity and clinical outcomes.
In collaboration with the American Cancer Society and the Centers for Disease Control and Prevention, the George Washington University Cancer Institute is launching the Cancer Survivorship E-Learning Series for Primary Care Providers on April 15, 2013.
Members of the public in sub-Saharan Africa who are carriers of the hereditary disease sickle cell disease must be educated aggressively through public health campaigns to raise awareness of the risks of parenting offspring with the disease if their partner is also a carrier, according to research published in the International Journal of Medical Engineering and Informatics.
› Verified 8 days ago
Ivy L Thurston, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 203 S State St, Big Rapids, MI 49307 Phone: 231-629-8665 | |
Dr. Roman Zolotoy, Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 20095 Gilbert Rd Ste B, Big Rapids, MI 49307 Phone: 231-592-1360 Fax: 231-592-1361 |